Compare FOUR & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FOUR | LQDA |
|---|---|---|
| Founded | 1999 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.1B |
| IPO Year | 2020 | 2020 |
| Metric | FOUR | LQDA |
|---|---|---|
| Price | $44.48 | $39.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 11 |
| Target Price | ★ $79.05 | $41.00 |
| AVG Volume (30 Days) | ★ 1.3M | 966.9K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.81 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,180,000,000.00 | $158,320,000.00 |
| Revenue This Year | $23.83 | $278.87 |
| Revenue Next Year | $14.30 | $57.13 |
| P/E Ratio | $27.53 | ★ N/A |
| Revenue Growth | 25.50 | ★ 1031.18 |
| 52 Week Low | $39.91 | $11.85 |
| 52 Week High | $107.16 | $46.67 |
| Indicator | FOUR | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 44.83 | 56.54 |
| Support Level | $43.32 | $35.00 |
| Resistance Level | $51.65 | $42.00 |
| Average True Range (ATR) | 2.37 | 1.85 |
| MACD | -0.10 | -0.07 |
| Stochastic Oscillator | 18.06 | 56.21 |
Shift4 Payments Inc is an independent provider of software and payment processing solutions in the U.S., expanding internationally. Its payments platform offers integrated products and services across in-store, online, mobile and tablet-based channels, including end-to-end payment processing, merchant acquiring services, a proprietary omni-channel gateway, eCommerce capabilities, and reporting tools. The company distributes its services through internal sales teams and partners, including independent software vendors (ISVs) and value-added resellers (VARs). Revenue is predominantly recurring, derived mainly from processing fees and subscription revenue from POS software, business intelligence tools and other technology solutions. The company derives maximum revenue from the United States.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.